We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Array BioPharma and Genentech Expand Strategic Oncology Collaboration
News

Array BioPharma and Genentech Expand Strategic Oncology Collaboration

Array BioPharma and Genentech Expand Strategic Oncology Collaboration
News

Array BioPharma and Genentech Expand Strategic Oncology Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Array BioPharma and Genentech Expand Strategic Oncology Collaboration "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Array BioPharma has announced the second extension and expansion of its collaboration with Genentech, Inc. for the discovery of targeted small molecule drugs for the treatment of cancer.

Under the terms of this expanded agreement, Genentech may provide approximately $50 million in research funding to access Array's Drug Discovery Platform over the next three years.

Array will be entitled to receive milestone payments based on the selection and progression of clinical drug candidates, as well as royalties on net sales of any products that may result from the collaboration.

Genentech will have the sole responsibility for clinical development and commercialization of any resulting products.

Genentech and Array entered into research collaboration in January 2004 to advance two of Array's oncology programs into clinical development.

In April 2005, the agreement was expanded to include an additional protein target in the field of oncology.

Under the terms of the amended agreement Array will receive further consideration based on the expanded scope and term of the agreement.

“We believe our collaboration with Genentech further validates Array's leadership position in cancer research,” said Robert E. Conway, Chief Executive Officer, Array BioPharma.

“This collaboration leverages Array's proprietary small molecule drug discovery expertise with Genentech's cancer expertise, with the goal of creating products to address one of the world's largest unmet medical needs and market opportunities.”

Advertisement